Перейти к контенту
Main image
Печать
Suramin, Sodium Salt 1PC X 50MG
Кат. №: 574625-50MG
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Печать
Suramin, Sodium Salt 1PC X 50MG
Main image
Кат. №: 574625-50MG
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Main image
Печать
Suramin, Sodium Salt 1PC X 50MG
Кат. №: 574625-50MG
Производитель: Sigma-Aldrich
Кол-во:
Цена по запросу
Товар оформляется под заказ
Description General description A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids. Packaging 50 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: no Primary Target protein tyrosine phosphatases Product does not compete with ATP. Reversible: yes Target IC50: 15 µM against phospholipase D Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C. Other Notes Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130. Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346. Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808. Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281. Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443. Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717. Denhertog, A., et al. 1992. J. Physiol.454, 591. Nakajima, M., et al. 1991. J. Biol. Chem.266, 9661. Wilks, J.W., et al. 1991. Int. J. Radiat. Biol.60, 73. Huang, R.C., et al. 1990. Mol. Pharmacol.37, 304. Kopp, R. and Pfeiffer, A. 1990. Cancer Res.50, 6490.
Related Categories
Biochemicals and Reagents, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Enzymes, Inhibitors, and Substrates, R to Z, Topoisomerase I More... Quality Level
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.
Description General description A reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids. Packaging 50 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: no Primary Target protein tyrosine phosphatases Product does not compete with ATP. Reversible: yes Target IC50: 15 µM against phospholipase D Warning Toxicity: Standard Handling (A) Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C. Other Notes Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130. Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346. Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808. Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281. Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443. Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717. Denhertog, A., et al. 1992. J. Physiol.454, 591. Nakajima, M., et al. 1991. J. Biol. Chem.266, 9661. Wilks, J.W., et al. 1991. Int. J. Radiat. Biol.60, 73. Huang, R.C., et al. 1990. Mol. Pharmacol.37, 304. Kopp, R. and Pfeiffer, A. 1990. Cancer Res.50, 6490.
Related Categories
Biochemicals and Reagents, Enzyme Inhibitors, Enzyme Inhibitors by Enzyme, Enzymes, Inhibitors, and Substrates, R to Z, Topoisomerase I More... Quality Level
Дорогой клиент, на сайте внедрена нейросеть для сбора информации о товаре. Это может привести к незначительным расхождениям в характеристиках продукции.